IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical DevelopmentGlobeNewsWire • 06/02/23
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and LenvimaPRNewsWire • 06/02/23
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid ArthritisGlobeNewsWire • 05/31/23
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical UpdateGlobeNewsWire • 05/30/23
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023PRNewsWire • 05/16/23
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/12/23
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/23
Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)PRNewsWire • 05/04/23
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/13/23
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/30/23
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/30/23
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023GlobeNewsWire • 03/27/23
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®PRNewsWire • 03/14/23